Category: ACN Newswire

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - On the evening of 30 March, Fosun International announced its 2025 annual results. During the Reporting Period, the Group’s total revenue reached RMB173.43 billion, and adjusted industrial operation profit was RMB4 billion.Compared to prior years, Fosun’s results have remained solid. However, pursuant to the principle of prudence, Fosun made one-off non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments, resulting in a book loss of RMB23.4 billion in 2025, of which real estate-related impairment accounted for approximately 55%, while impairment of non-core assets accounted for approximately 45%.Fosun emphasized in the announcement that these provisions do not affect the Company’s overall operations and cash flow. However, Guo Guangchang, Chairman of Fosun International, offered a sincere apology in this year’s Letter to Shareholders, stating that “A loss is never desirable.” He further explained that, “Under the current market conditions, some of the projects we invested in years ago are now valued differently from what we expected at the time of investment. Accordingly, the Board has taken a prudent decision to complete this asset impairment, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas. At a time when the global economy is generating opportunities amid volatility and China’s innovation-driven industries are gaining growth momentum, deepening our strategic focus now allows us to optimize our asset structure and helps us secure a stronger position in key sectors, positioning Fosun as a leaner, healthier, and more sustainable company.”In recent years, Fosun has steadily advance its strategy of “streamlining operations and strengthening the business, focusing on core businesses”, generating approximately RMB75 billion in cash returns from asset and business divestments. This round of impairments marks Fosun’s decisive step to clear accumulated risks on a one-off basis and shed “historical burdens”. While the book loss appears significant, from the capital market’s perspective, Fosun’s share price has rebounded more than 10% since the announcement of its results preview on 6 March, indicating the market has recognized and accepted its “risk clearance”.In his Letter to Shareholders, Guo Guangchang described this asset impairment as “repairing the roof on a sunny day”. Fosun International’s results announcement offers a clear illustration. Fosun’s core businesses has continued to deliver steady profits, reflecting solid operating fundamentals. At the same time, its long-established innovation and globalization strategies have become the core growth drivers for the Company. Collectively, these achievements underpin Fosun’s confidence in proceeding with “risk clearance” at this stage.Business fundamentals remain solid, pharmaceuticals and insurance segments deliver strong resultsLet’s start with Fosun’s business fundamentals. In 2025, Fosun International’s four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group’s total revenue. This demonstrates the results of Fosun’s strategic adjustment of “focusing on core businesses”, effectively addressing prior market concerns over “diversification”.Among them, Fosun Pharma, a core subsidiary of Fosun, achieved a net profit attributable to shareholders of the parent of RMB3.371 billion in 2025, representing a year-on-year increase of 21.69%. Fosun Pharma’s biopharmaceutical innovation platform, Henlius, recorded revenue of RMB6.667 billion and net profit of RMB827 million, delivering growth in both revenue and net profit for the third consecutive year.Next, let’s take a look at Fosun’s most important overseas subsidiary, Fosun Insurance Portugal. In 2025, Fosun Insurance Portugal achieved strong growth in revenue and net profit. Its net profit attributable to owners of the parent amounted to EUR201 million, up 15.8% year-on-year, establishing it as a stable contributor to Fosun’s profitability. Fosun Insurance Portugal has benefited significantly from Fosun’s global ecosystem, expanding its presence from Portugal to overseas markets such as Europe, Latin America and Africa. In 2025, Fosun Insurance Portugal received its inaugural A rating from S&P Global, reflecting international recognition of its asset quality and risk resilience.In Chinese mainland, Fosun’s two insurance companies have also performed well. Pramerica Fosun Life Insurance’s premium income for the year reached RMB13.28 billion, up 41.6% year-on-year, while net profit surged over 492% to RMB650 million. Meanwhile, Fosun United Health Insurance recorded insurance income of RMB7.84 billion in 2025, representing a year-on-year increase of 50.1%, with net profit reaching RMB139 million, marking five consecutive years of profitability.Core drivers: innovation and globalization strategiesFosun Pharma and Fosun Insurance Portugal embody Fosun’s two core strategies: innovation and globalization.Since its establishment, Fosun has always regarded “innovation-driven research and development (R&D)” as its core strategy, and began its global expansion following its listing in Hong Kong. After years of intensive investment and exploration, innovation and globalization strategies have become the core driving forces behind Fosun’s development, consistently delivering results that generate “compounding returns” over time.The biggest change for Fosun Pharma in 2025 was strong growth in its innovative drug breakthroughs. During the Reporting Period, Fosun Pharma’s revenue from innovative drugs reached RMB9.893 billion, representing a year-on-year increase of 29.59%, accounting for 33.16% of its pharmaceutical business revenue. Fosun Pharma had 16 indications of its 7 innovative drugs approved for marketing in China and overseas markets, while marketing applications for 6 innovative drug candidates were accepted.During the Reporting Period, nearly 40 of Fosun’s innovative drug clinical trials were approved by regulatory authorities in China, the United States and Europe, while multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth.Henlius’ HLX43 remains the main focus of market interest. As a PD-L1-targeted antibody drug conjugate (ADC) with potential best-in-class characteristics and broad anti-tumor activity across multiple tumor types, HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, esophageal squamous cell carcinoma (ESCC), and other indications. On 27 January 2025, it was approved for clinical trials in Chinese mainland, positioning it to become another landmark product for Fosun.This year, Fosun’s international business development (BD) efforts for innovative drugs made a notable impression on the market. For example, at the beginning of 2026, Fosun Pharma entered into an agreement with Eisai Co., Ltd. in relation to HANSIZHUANG, with a potential total value of over USD300 million. At the end of 2025, Fosun Pharma’s subsidiary, Yao Pharma, signed a global exclusive licensing agreement with Pfizer, with a potential total value of over USD2 billion; Fosun Pharma Industrial entered into a strategic collaboration with biotechnology company Clavis Bio, with Fosun Pharma eligible to receive up to USD7.25 billion in payments.In terms of globalization, Fosun has established a profound business presence in more than 40 countries and regions worldwide. Today, it has achieved comprehensive globalization across products, services, and brands. In 2025, Fosun’s overseas revenue reached RMB94.86 billion, accounting for 54.7% of total revenue, representing a year-on-year increase of 5.4 percentage points. Fosun’s globalization strategy has evolved from “acquiring globally” to “earning globally”.Club Med, a subsidiary of Fosun Tourism Group, operates 67 resorts worldwide. During the Reporting Period, Club Med once again achieved record-high performance, with revenue reaching RMB18.07 billion, representing a year-on-year increase of 3.6%, while operating profit reached RMB1.44 billion, up 4.6% from 2024.Hainan Mining, a subsidiary of Fosun, has now developed into a global resource + new energy company and has made remarkable strides in its global expansion. Hainan Mining’s model of “overseas resources + processing in Hainan” entered a substantive operational stage in 2025. Its Bougouni Lithium Mine in Mali produced 45,000 tons of lithium concentrate, with the first shipment of 30,000 tons arriving at Yangpu Port in Hainan in January 2026. Additionally, through its subsidiary Roc Oil and the newly acquired oilfield project in Oman, Hainan Mining has accelerated the building of a “minerals + energy” network spanning West Africa, the Middle East, and Southeast Asia.International rating agencies affirm Fosun International’s rating outlook as “stable”Fosun’s financial position remains the market’s primary focus.According to Fosun International’s results announcement, during the Reporting Period, cash, bank balances and term deposits amounted to RMB61.1 billion; unutilized banking facilities amounted to RMB144.6 billion; total debt to total capital ratio was 57%. Fosun has maintained a healthy financial position, with ample cash reserves. International rating agencies have broadly affirmed Fosun International’s rating outlook as “stable”.Guo Guangchang stated in his Letter to Shareholders that, at present, Fosun’s core businesses remain solid, liquidity position is robust, and banking relationships remain stable. The Company’s major shareholder and management team have announced plans to increase their holdings in the shares of the Company and the Company will also proceed with a share buyback program. With Fosun’s core businesses continuing to grow and strategic plans firmly on track, “We are confident in our ability to support a return of the share price to fair value and better protect the long-term interests of our shareholders.”In addition to its results announcement, Fosun announced that it is committed to increasing its dividend payout ratio, targeting an increase from the current 20% to 35% for the 2026 financial year. Based on the accumulated distributable profit of the Company, the dividend for the 2026 financial year is expected to be not less than HKD1.5 billion.We can reasonably expect that this round of “strategic streamlining” will inject greater certainty into Fosun’s future business growth.In this year’s Letter to Shareholders, Guo Guangchang also disclosed Fosun’s medium-term financial goals: “We strive to gradually restore annual profit to the RMB10 billion level; at the group level, we aim to generate RMB60 billion in cash returns, reduce total debt to below RMB60 billion, and strive to achieve an investment-grade rating.” He stated that, “Fosun has always stayed true to its original aspiration: to do the right things, the difficult things and the things that take time to develop. For Fosun’s future, we do not seek short-term gains; we seek to build a foundation for lasting success.” Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - March 31, 2026, Legend Holdings Corporation (“Legend Holdings” or the “Company”; Stock Code: 3396.HK) announced the audited annual results for the year ended December 31, 2025 (the “Reporting Period”). The Company recorded revenue of RMB605,945 million, representing an 18% year-on-year increase; the net profit was RMB9,799 million, representing a 28% year-on-year increase; the net profit attributable to equity holders of the Company was RMB1,061 million, representing a significant year-on-year increase. The profit growth was primarily attributable to the recovery of the capital market, which led to a year-on-year reduction in losses from the industrial incubations and investments segment. In addition, the Board has recommended a final cash dividend of RMB0.10 per ordinary share (before tax).In 2025, the Chinese economy continued to demonstrate strong resilience. As the conclusion year of the 14th Five-Year Plan, there was a prominent focus on high-quality and innovative development. Adhering to its original aspiration of serving the country through industry, Legend Holdings closely aligned with national strategic directions, ventured into the deep waters of scientific and technological innovation, focused on the real economy, and worked with all sectors of society to foster and develop new quality productive forces.Build a Distinctive Sci-Tech Innovation System to Drive High-Quality DevelopmentLegend Holdings has actively responded to the national innovation-driven development strategy and continued to increase investment in R&D. In 2025, R&D expenses exceeded RMB17 billion, representing a year-on-year increase of 10% and reaching a new historic high. During the 14th Five-Year Plan period, the total R&D expenses exceeded RMB75 billion, marking an increase of over 60% compared to the 13th Five-Year Plan period. This firm commitment to R&D has yielded remarkable returns. The launch of the world’s first AI PC has led industry transformation, and the Company currently captures a global PC market share of over 25%, firmly ranking first in the industry. Its AI servers and Neptune liquid cooling systems have gained high recognition in the global market, placing the Company among the world’s top three server providers. The SSG services claimed the top rankings in China’s IT services sector, and a series of generative AI solutions have been launched, leading the industry’s transition from IT services to AI-driven services.During the same period, Legend Holdings has actively participated in the construction of China’s technology ecosystem and scaled up its investment in frontier domestic technologies. Focusing on national emerging pillar industries and future industries, the Company has maintained an investment pace of over 100 new and follow-on investments each year in Chinese tech enterprises across cutting-edge sectors including artificial intelligence (AI), embodied intelligence, commercial aerospace, the low-altitude economy, new energy and advanced materials, controllable nuclear fusion, semiconductors, quantum computing, and biopharmaceuticals. In AI alone, the Legend Holdings family group has invested in over 300 enterprises, making it the institution with the longest investment history and the broadest reach in China’s AI field. In 2025, the Company invested in nearly 150 Chinese tech enterprises and facilitated the listing of 15 portfolio companies on capital markets, ranking among the top performers in the market.In response to the national call for “deep integration of technological and industrial innovation”, Legend Holdings has actively fulfilled its role as a main entity in corporate technological innovation. The Company’s Forward-Looking Technology Research Institute has intensified exploration into the industrialization of early-stage cutting-edge technological achievements. It has established connections with over 60 enterprises and research institutions, launched in-depth cooperation with two universities and seven domestic and international enterprises, and selected 39 seed technologies. Earlier this year, the “Peking University-Legend Holdings Advanced Photonic Integration Technology Joint Laboratory” established in collaboration with the State Key Laboratory of Photonics and Communications at Peking University, stands as a representative example of such efforts.In addition, the Legend Holdings family group achieved multiple results in cutting-edge and core technology localization. Lenovo Research Institute, under Lenovo Group, has been driving innovation in the AI domain, launching world-leading L3 AI super agents, such as Lenovo Tianxi and Lenovo Qira, and developing the X-Engine on-device inference engine to significantly enhancing the AI PC experience. Levima Research Institute, under Levima Advanced Materials, has focused on advanced materials, filling domestic gaps in areas such as solid-state and semi-solid-state battery materials and PEEK materials. Two research projects jointly developed with the Chinese Academy of Sciences have both been designated national Key R&D Programs by the Ministry of Science and Technology.Focusing on the Real Economy and Strengthening the Industrial FoundationDuring the 14th Five-Year Plan period, Legend Holdings has been deeply rooted in the real economy. With advanced manufacturing as its backbone, the Company has made new investments totaling over RMB20 billion, with the estimated output value exceeding RMB100 billion. Within this framework, Lenovo has built its “global mother factory” of intelligent manufacturing, the Shenzhen southern base, which has earned the highest certification under China’s Intelligent Manufacturing Capability Maturity Model. Lenovo Tianjin Industrial Park has also earned “Eco-level Carbon Neutral Factory” certification, a top-tier designation globally. By establishing four major manufacturing bases across China, Lenovo has ensured the stability and security of China’s IT-related industrial and supply chains, while driving local economic progress. Levima Advanced Materials established its New Energy Materials and Biodegradable Materials Integration Project in Levima Green (Shandong) Advanced Materials Co., with an annual capacity of 200,000 tons of EVA and 300,000 tons of PO. In Jiangsu, Levima Advanced Materials established a 100,000-ton-per-year POE (polyolefin elastomer) project. Furthermore, it has established multiple projects across several locations, including the biodegradable PLA and ultra-high-molecular-weight polyethylene (UHMWPE), filling critical gaps in China’s relevant industrials.Deepening ESG Practices and Cultivating Diverse ValuesLegend Holdings remains steadfast in its commitment to green development, pursuing the harmonious integration and mutual enhancement of economic, social, and environmental values. Lenovo has maintained the highest AAA rating in the MSCI ESG Ratings for four consecutive years. It has pledged net-zero greenhouse gas emissions across its entire value chain by the end of 2050, and made itself the first high-tech manufacturing enterprise in China to receive the Science Based Targets initiative’s (SBTi) net-zero validation. Levima Advanced Materials has built a portfolio of green products centered on green industries. it has reinforced its leadership in the photovoltaic adhesive film materials industry while expanding into fields such as biodegradable materials and new energy battery materials and was designated a National Green Factory. Furthermore, Legend Holdings actively fulfills its corporate social responsibility in areas such as technological innovation and rural revitalization. Notably, the Legend Star CEO Training Program provides free entrepreneurship training to domestic technology founders. Since its inception, Legend Holdings has invested tens of millions of RMB annually. As of the end of 2025, the cumulative investment reached RMB160 million, with a total of 1,429 innovative and entrepreneurial talents cultivated. To date, 71 enterprises founded by these "Star Alumni" have successfully gone public, and 216 have been recognized as National-level Specialized, Refined, Distinctive and Innovative "Little Giant" Enterprises, driving the creation of nearly 460,000 jobs in society.Consolidating Strategic Focus and Anchoring the Future through Intelligent TransformationGuided by the agenda of high-quality development, Legend Holdings has strengthened independent innovation, steadily advanced the optimization of its asset portfolio, and enhanced capital recycling. Over the past five years, the Company has recovered a total of over RMB45 billion in capital, providing robust support for its large-scale investments in technological innovation and the real economy.Looking ahead to the 15th Five-Year Plan period, Legend Holdings will more proactively integrate into the tide of high-quality development, strengthen the guidance of technological innovation, focus on the real economy, solidly promote the development of new productive forces with the strategic focus of long-termism, and resolutely implement the transformation of major scientific and technological achievements, supporting high-level technological self-reliance and self-improvement. The Company will continue to increase R&D investment in national emerging pillar industries such as AI and new materials; maintain systematic support for China's sci-tech innovation ecosystem and innovative and entrepreneurial enterprises; accelerate the adjustment of its asset portfolio to build an industrial layout that aligns with the characteristics of the times; drive collaborative innovation across diverse businesses to create a differentiated innovation ecosystem; and establish a replicable business model with Legend characteristics in the commercialization of global cutting-edge technologies, continuously delivering results. In addition, Legend Holdings will further consolidate its industrial foundation, strengthen core competitiveness, actively fulfill social responsibilities, and contribute to the building of a Beautiful China.Mr. Ning Min, Chairman and Executive Director of Legend Holdings, stated: “Over the past year, Legend Holdings has delivered a resilient and quality-improved performance, guided by a clear technological innovation strategy and supported by the vast market space brought about by the country's promotion of new productive forces and the construction of a modern industrial system. We will firmly seize the strategic opportunities of the 15th Five-Year Plan period, and through more determined steps in innovation, a more open industrial ecosystem, and more pragmatic social contributions to align the development of the enterprise with national development, creating greater value for shareholders and society and being a steadfast practitioner of the Chinese path to modernization.” Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - Bringing artificial intelligence from the laboratory to a broad spectrum of industries—particularly in the B2B market—demands that AI companies overcome a formidable set of challenges: how to precisely match complex, ever-evolving business scenarios; how to achieve scalable delivery; and how to establish a sustainable business model.Extreme Vision, based in Qingdao, Shandong, has delivered its answer through a compelling set of metrics. As of September 30, 2025, the Company had completed over 6,000 projects, recorded a product repurchase rate exceeding 80%, and served more than 100 industries, including manufacturing, energy, retail, and transportation. Revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate of 59.2%. The Company turned profitable in 2024.A Platform-based Approach to Tackling the Fragmentation ChallengeExtreme Vision was founded by three entrepreneurs born in the 1990s: Mr. Chan Chan Kit, Ms. Luo Yun, and Mr. Chen Shuo. Mr. Chan Chan Kit holds a direct stake of 16.05% in the Company and serves as its largest shareholder, legal representative, chairman of the board, executive director, and general manager. The three founders, all alumni of Sun Yat-sen University, first conceived the idea of starting a business during their undergraduate studies.“The biggest challenge in the B2B market is fragmentation,” Mr. Chan once noted. Different industries, different enterprises, and even different production processes within the same company all have vastly different AI requirements. If each scenario requires developing algorithms from scratch, the cost is prohibitive, the timeline is protracted, and scaling becomes virtually impossible. This is precisely the “B2B chasm” that many AI companies struggle to cross. Based on this insight, Extreme Vision pioneered the AI Vision Algorithm Marketplace.As of September 30, 2025, Extreme Vision’s algorithm marketplace has launched 1,517 algorithms, including 1,369 algorithms co-developed with third-party developers. Covering application scenarios in over 100 industries, the platform has served more than 3,000 customers and delivered over 6,000 projects since its establishment. Notably, the product repurchase rate has exceeded 80%, reflecting the strong standardization of its solutions and robust market recognition.Self-developed AI infrastructure empowers efficient implementation. The Company’s self-developed AI infrastructure enables efficient algorithm development and rapid solution development. On the one hand, leveraging its self-developed full-stack technology platform, Extreme Vision has built an industry-leading AI infrastructure that covers the entire lifecycle, including data annotation, model training, algorithm development, algorithm testing and inference deployment. On the other hand, the integrated tool engines within its AI development infrastructure significantly lowering the barriers to algorithm development and drastically reducing the time required for customized algorithm development.Multi-industry Implementation: Project Practice as a Driver for Healthy GrowthLeveraging its platform-based capabilities, Extreme Vision has applied its technology to real-world business scenarios across various sectors, delivering actionable and reusable solutions.In terms of industrial manufacturing, Extreme Vision deployed an EHS+AI intelligent monitoring system for CR Beer. By implementing 25 categories of risk-identification algorithms, the system accurately captures risk scenarios such as the improper wearing of safety ropes and goggles, hoisting operations, and unauthorized personnel intrusion during equipment operation. This has successfully transformed traditional passive safety management into proactive, real-time, and automated risk control.In terms of environmental and energy sectors, Extreme Vision has built an intelligent security management platform, “Halo Guard” for China Everbright Environmental Energy. Equipped with nearly 30 AI vision algorithms for safety management and control, the platform conducts real-time monitoring of high-risk operational scenarios such as unloading platforms and burning zones, significantly enhancing operational safety.In the higher education sector, Extreme Vision has jointly established the “Artificial Intelligence Comprehensive Practice Center” with the School of Smart City at Beijing Union University. Leveraging its Extreme Flow platform, the Company supports algorithm teaching and research in universities, helping to cultivate AI talent.In the transportation and mobility sector, Extreme Vision has identified new application scenarios for large model solutions. Using large model technologies, the Company has generated autonomous driving simulation scenario data and conducted hallucination detection for a leading automotive retailer, helping the client reduce reliance on real-world road data collection and optimize the R&D process.These projects not only demonstrate the breadth and depth of Extreme Vision's technology implementation but also collectively underpin the Company's sustained growth. Each successfully delivered project generates experience and reusable modules for future projects, creating a virtuous cycle that contributes to a product repurchase rate of over 80%.Profitability Continuously Validated, Large Model Emerges as a New Growth DriverAs its commercial value continues to be validated, Extreme Vision's profitability has also shown strong growth momentum. The Company's revenue grew from RMB101.6 million in 2022 to RMB257.3 million in 2024, representing a compound annual growth rate (CAGR) of 59.2%. The gross profit margin improved from 30.6% in 2022 to 40.2% in 2024. The Company recorded a profit of RMB8.71 million in 2024, making it one of the few profitable AI vision companies in China. For the nine months ended September 30, 2025, the Company achieved revenue of RMB136.3 million, a year-on-year increase of 71.7%, with the gross profit margin further rising to 44.9%.Notably, the large model solutions launched by the Company in 2024 contributed RMB62.12 million in revenue, accounting for 24.1% of total revenue. This has become a new growth driver and is expected to unlock further market opportunities.In terms of R&D investment, the Company continued to increase its efforts. R&D expenditure reached RMB44.82 million in 2024, an increase of 22.6% compared to 2023. As of September 30, 2025, the Company had a professional team of 101 R&D personnel. According to the Prospectus, the Company intends to use approximately 60.0% of the net proceeds from the IPO (HK$260.6 million) to enhance R&D capabilities, including the construction of large models and AI infrastructure, as well as the upgrade of AI-PaaS middleware.Broad Market Prospects: The Platform Flywheel AcceleratesIndustry prospects are promising. According to Frost & Sullivan, the market size of China’s emerging enterprise-level computer vision solutions is projected to grow from RMB11.1 billion in 2024 to RMB97.0 billion in 2029, representing a CAGR of 54.3%. This represents an almost eightfold increase in market size over the next five years, indicating strong inherent growth potential in the sector.As large models gain traction globally, market expectations for AI have been further elevated. However, in the B2B market, no matter how cutting-edge the technology is, it must ultimately return to the simple logic of “usability, practicality, and cost controllability.” Extreme Vision's experience shows that a competitive edge for AI companies lies not only in technological leadership but also in the ability to develop standardized solutions for complex industrial scenarios and scale them through platforms and ecosystems.From algorithms to applications, from project delivery to customer retention, Extreme Vision has remained committed to its mission of pushing technological boundaries and harnessing technology for good—building an AI flywheel that continuously generates commercial value. As AI technology permeates all industries, from industrial safety and energy inspection to retail operations, the demand for fragmented long-tail scenarios continues to emerge, positioning Extreme Vision for accelerated growth. However, whether it can continuously increase market share and improve cash flow amid fierce competition remains a core challenge post-listing. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 31, 2026 - (ACN Newswire via SeaPRwire.com) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts.Return to Profitability Driven by Vaccine Portfolio GrowthAccording to its annual results, CanSinoBIO achieved total revenue of approximately RMB 1.068 billion, representing a year-on-year increase of 26.18%. Net profit attributable to shareholders reached RMB 27.9 million, marking a return to profitability.The turnaround reflects more than a cyclical rebound and suggests the company is building a more sustainable revenue base through the commercialization of routine vaccines. This has strengthened its ability to generate consistent cash flow.The improvement was driven primarily by organic growth in core operations rather than one-off factors. During the reporting period, the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (trade name: Menhycia(R)) maintained steady revenue growth, while its 13-valent Pneumococcal Conjugate Vaccine (trade name: iPneucia(R)) gained market traction following its launch. A more balanced revenue mix has improved earnings visibility.In addition, CanSinoBIO received multiple government grants and international R&D funding support during the year, reflecting recognition of its technological capabilities and innovative value.Core Products Set to Scale Up, Pipeline Supports Future GrowthBeyond near-term earnings, the company is supported by a diversified pipeline that provides both mid- and long-term growth drivers.As a core growth driver for CanSinoBIO, Menhycia(R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to expand its market reach. In February 2026, the company announced that the supplemental application to expand the age range of applicable population of Menhycia(R) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved, further broadening its target population.Meanwhile, iPneucia(R)—China’s first 13-valent pneumococcal conjugate vaccine using a dual-carrier system (CRM197 and tetanus toxoid)—is expected to generate commercial synergies with Menhycia(R). Shared distribution and marketing channels could help lower marginal sales costs and improve overall efficiency.In addition, the company’s mid-term pipeline remains robust. It’s absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the “DTcP”) for infants (below 2 years old) (the “DTcP Infant”)has been included in the priority review pathway, which will accelerate its approval timeline.To date, no component-based DTaP vaccine developed by domestic manufacturers has been approved for market launch in China. The infant DTcP vaccine is formulated with individually purified pertussis antigens in defined ratios to ensure consistent quality and stability. Its development also lays the groundwork for adolescent and adult component Tdap vaccines and combination vaccines, enhancing the Company’s product portfolio and core competitiveness.From near-term delivery to mid-term development and long-term innovation, CanSino Biologics’ value goes beyond its existing productsR&D Capabilities Support Long-Term CompetitivenessAs a leading innovative vaccine company, CanSinoBIO consistently adheres to a long-term strategy, ensuring the company remains at the forefront of technological exploration and laying a solid foundation for its sustained competitiveness.Its core talent team brings an average of more than 25 years of industry experience across global pharmaceutical and biotechnology companies, spanning research, manufacturing and commercialization. This has enabled the company to establish an integrated development system aligned with international standards and covering the full development cycle from early-stage research to commercialization.Over time, CanSinoBIO has also built five core technology platforms, including viral vector vaccines, synthetic vaccines, protein structure design and Virus-Like Particle (VLP) assembly, mRNA vaccines, and formulation and delivery technologies. These platforms support a diversified innovation system and provide a solid foundation for lifecycle vaccine development.The company continues to focus on differentiated innovation, including multivalent combination vaccines and novel delivery technologies, with the aim of developing globally competitive vaccine products.These technological capabilities have supported the launch of products like Menhycia(R) and iPneucia(R), reinforcing the company’s position in the vaccine sector.International Expansion Gains MomentumMeanwhile, amid intensifying competition in the domestic vaccine market, CanSinoBIO is accelerating its international expansion.Recently, the company announced that its manufacturing facility has passed the PIC/S GMP certification issued by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). PIC/S is an internationally recognized framework for pharmaceutical inspection and certification, comprising regulatory agencies from over 50 countries. This certification not only confirms that Menhycia(R) and iPneucia(R) meet international-quality standards but also enhances the company’s prospects for entering additional global markets.In fact, the Company’s international presence is well established, with Menhycia(R) obtaining Indonesian registration and Halal certification since 2024.The company has also entered into multiple strategic partnerships abroad, covering commercialization, joint R&D, clinical trials, and localized production. Through a “technology transfer + local manufacturing” approach, CanSinoBIO is expanding its presence beyond product exports toward broader technology-based collaboration.Growth Catalysts Point to Potential Re-RatingOverall, the latest results suggest CanSinoBIO is moving through an inflection point, supported by clearer commercialization pathways.Yet, its current market valuation may not fully reflect its investment potential. Looking ahead, potential growth drivers include the expanded indication for Menhycia(R), continued ramp-up in iPneucia(R) sales, the infant DTcP vaccine currently under priority review, as well as further international market expansion. At the same time, China’s policy support for biopharmaceuticals as a strategic sector could provide a favorable backdrop for valuation.As earnings continue to improve and market expectations adjust, the company may see both earnings growth and a re-rating in valuation multiples. Against the backdrop of China’s rising focus on biopharmaceutical innovation, CanSinoBIO’s long-term investment case is increasingly difficult to ignore. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Performance Highlights:- Revenue: RMB1,622.4 million, representing a year-on-year increase of 40.5%- Net Profit: RMB106.1 million, representing a year-on-year increase of 74.8%- Adjusted Net Profit (a non-IFRS measure): RMB135.4 million, representing a year-on-year increase of 111.9%- In 2025, the Group opened 156 new restaurants, comprising 134 self-operated restaurants and 22 franchised restaurants- As of December 31, 2025, the Group operated 395 self-operated restaurants and 92 franchised restaurants across 24 cities in Mainland China, 15 restaurants in the Hong Kong Special Administrative Region and 1 restaurant in SingaporeHONG KONG, Mar 30, 2026 - (ACN Newswire via SeaPRwire.com) - Guangzhou Xiao Noodles Catering Management Co., Ltd. (the “Company” or “Xiao Noodles”; Stock Code: 2408.HK) is pleased to announce that the board of directors of the Company announces the unaudited consolidated results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2025 (the “Reporting Period”).As the “First-listed Chinese Noodle Restaurant” on the Hong Kong Stock Exchange, the Group leveraged its standardized operational system and core product strengths in 2025 to comprehensively drive store expansion and optimize its business portfolio. Through synergies across its business segments, the Group achieved significant revenue growth during a period of profound industry restructuring.During the Reporting Period, the Group generated revenue of RMB1,622.4 million, representing a year-on-year increase of 40.5%; net profit reached RMB106.1 million, up 74.8% year-on-year; and adjusted net profit (a non-IFRS measure) amounted to RMB135.4 million, up 111.9% year-on-year. In 2025, the Group opened 156 new restaurants, including 134 self-operated restaurants and 22 franchised restaurants. As of December 31, 2025, the Group operated a total of 503 restaurants, comprising 395 self-operated and 92 franchised restaurants across 24 cities in mainland China, 15 restaurants in the Hong Kong Special Administrative Region, and one restaurant in Singapore, marking significant expansion achievements.Steady Growth in Self-operated Restaurants, Reinforcing the Core BusinessThe Group’s revenue primarily comes from self-operated restaurants operation and franchised restaurants management. Self-operated restaurants serve as the core revenue pillar, while franchised restaurants emerged as a new growth engine. The synergistic efforts of these two business segments are driving the Group’s continued improvement in profitability.In terms of self-operated restaurant business, in 2025, the operational quality and efficiency of self-operated restaurants continued to improve, with core operational indicators delivering outstanding performance. The Group’s revenue from self-operated restaurant operations increased from RMB1,001.0 million in 2024 by 44.9% to RMB1,450.2 million in 2025, primarily attributable to the increase in the number of self-operated restaurants. Revenue from self-operated restaurant operations as a percentage of total revenue increased from 86.7% in 2024 to 89.4% in 2025. In addition, revenue from delivery business as a percentage of total revenue increased rapidly from 15.6% for the year ended December 31, 2024 to 23.3% for the year ended December 31, 2025.During the Reporting Period, the average spending per order at the Group’s self-operated restaurants amounted to RMB29.9, remaining stable, while average daily orders per restaurant increased from 386 orders in 2024 to 406 orders in 2025, demonstrating improved customer attraction.In terms of same-store operating performance, it remained robust, with same-store sales amounting to RMB745.612 million, representing a year-on-year increase of 1.0› average daily orders per same store increased from 391 orders in 2024 to 427 orders in 2025, and the average spending per order at same stores was RMB29.4, remaining stable.In terms of franchised restaurants, in 2025, the Group’s franchised restaurant operations delivered excellent performance, with improvements across various core indicators. The Group’s revenue from franchise management increased from RMB152.5 million in 2024 by 12.3% to RMB171.3 million in 2025, primarily attributable to the increase in the number of restaurants.Steady Progress in Domestic and Overseas Expansion to Actively Explore New Growth OpportunitiesWhile maintaining the steady development of its existing business, the Group has actively expanded its business to the Hong Kong Special Administrative Region and overseas markets, steadily increasing market penetration and seeking new growth opportunities.As of December 31, 2025, the Group had successfully opened 15 restaurants in the Hong Kong Special Administrative Region and one restaurant in Singapore, marking initial achievements in its overseas market layout. During the Reporting Period, the Hong Kong market delivered an outstanding overall operating performance with remarkable results in regional expansion. Going forward, the Group plans to further expand into Southeast Asia to enhance its brand recognition, optimize its market layout, and drive long-term, steady and diversified revenue growth.Future OutlookLooking ahead to 2026, driven by a series of national policies to stabilize the economy and promote growth, China’s domestic economy and consumer market are expected to continue their recovery, with residents’ consumption capacity and confidence further strengthened, injecting strong impetus into the development of the Chinese fast food industry.Against this backdrop, the Group will firmly seize market opportunities, leverage its brand advantage as the "First-listed Chinese Noodle Restaurant", and promote the expansion of its restaurant network, with plans to open 150 to 180 new restaurants in 2026. Meanwhile, the Group will continue to increase investment in brand building to deepen brand recognition and influence, steadily advance its overseas market expansion, consolidate its leading position in the Chinese noodle restaurant segment, and strive to create greater value for shareholders.About Guangzhou Xiao Noodles Catering Management Co., Ltd.Guangzhou Xiao Noodles Catering Management Co., Ltd. is a Chinese noodle restaurants operator in China. We operate the Xiao Noodles brand in the Chinese Mainland and Hong Kong SAR. Our restaurant network encompassed 395 self-operated restaurants and 92 franchised restaurants across 24 cities in the Chinese Mainland and 15 restaurants in Hong Kong SAR and one restaurant in Singapore as of December 31, 2025. According to Frost & Sullivan, the Company ranked fourth largest Chinese noodle restaurants operator in China in terms of GMV in 2024. Based on the same source, we ranked the thirteenth in the overall Chinese QSR market in terms of GMV in 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 30, 2026 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company", Stock Code: 6922.HK), an innovative medical device platform company with a main focus on the field of minimally-invasive interventional cryotherapy, recently announced its annual results for the year ended December 31, 2025. The report highlights that the Company's commercialization process has comprehensively accelerated, delivering exceptional performance across core financial metrics. Alongside exponential revenue growth, Cryofocus achieved significantly improved operational efficiency and drastically narrowed losses, demonstrating its robust growth momentum and intrinsic platform value.Robust Revenue Growth, Drastically Narrowed Losses, and Continuous Improvement in Operational QualityIn 2025, Cryofocus recorded a revenue of RMB 95.27 million, representing a surging increase of 78.0% compared to RMB 53.53 million in the same period of 2024. The loss for the year was significantly narrowed by 60.0% to RMB 44.46 million, down from RMB 111.28 million in 2024, showcasing the Company's outstanding operational efficiency and cost-control capabilities.The Company's overall gross profit reached RMB 63.98 million, a year-on-year increase of 66.6%, while the gross profit margin was maintained at a healthy level of 67.2%. During the reporting period, Cryofocus continued to optimize its R&D efficiency. R&D expenses decreased by 58.6% year-on-year to RMB 30.44 million, primarily due to the reduction in investments following the successful NMPA approval of certain products, as well as the optimization of staff costs. This reflects the steady transition of the Company's R&D pipeline from an early-stage investment phase to a late-stage harvest phase.Comprehensive Acceleration of the Cryotherapy Product Matrix with Respiratory Intervention as the Core Growth Engine The strong financial growth was primarily driven by the commercial volume ramp-up of the Company's cryotherapy product pipeline, which is built upon its unique liquid nitrogen cryoablation technology and advanced flexible catheter technology platforms. Notably, the respiratory intervention product pipeline delivered a stellar performance, acting as the absolute main driving force for revenue growth.In March 2025, the Company's Malignant Stenosis Cryoablation System received approval from the National Medical Products Administration (NMPA) and was successfully commercialized in China in May of the same year, with sales volume climbing rapidly. In addition, the sales of the previously commercialized Cryoadhesion System continued to grow. Meanwhile, the Company further deepened its distribution partnership with the international medical giant Boston Scientific (BSC) in the Chinese market, which contributed considerable incremental revenue.More notably, the Company's Asthma Cryoablation System was granted designation as a "Breakthrough Medical Device" by the U.S. Food and Drug Administration (FDA) in July 2025. This marks an international authoritative recognition of its innovative technology, laying a solid foundation for its future expansion into the global market.Successful Share Placement Fortifies Financial Foundation to Facilitate Global ExpansionTo support future R&D and market expansion, the Company successfully completed the placement of new H shares to specific investors in January 2026. A total of 5,595,000 H shares were issued, raising net proceeds of approximately HK$29.73 million. Cryofocus plans to utilize the funds primarily for the R&D, manufacturing, and commercialization of minimally-invasive interventional products related to vascular intervention, respiratory intervention, and cancer intervention, as well as to provide financial backing for the potential overseas business expansion of these commercialized products.This financing not only bolstered the Company's cash reserves, securing a solid financial guarantee for the clinical development and global registration of subsequent high-value pipeline products—such as the Peri-Pulmonary Nodule Cryoablation System, COPD Cryospray System, Asthma Cryoablation System, and the Cryo-RDN System for resistant hypertension—but also underscored the strong confidence of professional institutional investors in the Company’s technology platform and long-term prospects.Looking Ahead: Platform Advantages Highlighted, Striving to Become a Global Cryotherapy LeaderLeveraging its unique "One Platform, Multiple Tracks" business model, Cryofocus has built a robust product pipeline covering multiple therapeutic areas, including vascular intervention, respiratory intervention, and cancer intervention. The Company currently possesses a comprehensive pipeline comprising 25 products and product candidates, 11 of which have already been commercialized. As more products progressively enter late-stage clinical trials and the regulatory approval phase, the value of the Company's platform is expected to be continuously unlocked.Looking ahead, Cryofocus stated that it will continue to execute its clear strategies: rapidly advancing the clinical development and commercialization of product candidates; further expanding the product portfolio based on its core technology platform; continuously investing in underlying and supporting technologies; and selectively expanding its worldwide footprint. The Company is steadily transitioning from an R&D-driven approach to a dual-engine model driven by both R&D and commercialization, taking solid steps toward its vision of becoming a "global medical device platform in the field of minimally-invasive interventional cryotherapy." Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 29, 2026 - (ACN Newswire via SeaPRwire.com) - Condiments are an important carrier of Chinese culinary culture, playing an irreplaceable role in people’s daily diet, the upgrading of the catering industry, and the development of the food industry. As the absolute leader in the condiment industry, Foshan Haitian Flavouring & Food Co., Ltd. (A-share: 603288; H-share: 03288) delivered a high-quality performance report in 2025, leveraging its comprehensive product portfolio, leading digital and intelligent capabilities, and resolute internationalization strategy. The company continues to lead the industry and stands as a well-deserved industry benchmark.On 26th March, Haitian Flavouring released its 2025 annual report. Financial data shows that in 2025, the company achieved total revenue of RMB 28.873 billion, a year-on-year increase of 7.32%. Profitability improved simultaneously, with full-year net profit attributable to shareholders of the parent company reaching RMB 7.038 billion, up 10.95% year-on-year; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses amounted to RMB 6.845 billion, a year-on-year rise of 12.81%, and the gross profit margin of its core condiment business reached 41.78%, representing a year-on-year increase of 3.15 percentage points. All operating data hit record highs, demonstrating strong development resilience and core competitiveness, and further widening the gap with industry peers.Product Matrix Diversification: Building a Foundation for Multi-Dimensional GrowthAs a time-honored Chinese enterprise with a 400-year history deeply rooted in the condiment industry, Haitian Flavouring has built a stable and resilient multi-dimensional growth pattern through its continuously enriched product portfolio for the mass market, with its core product categories maintaining a globally leading competitive position.In the soy sauce category, Haitian Flavouring has always adhered to a consumer-centric approach. Focusing on consumers’ diverse needs, the company has continuously innovated in flavor, functionality, and specifications, establishing a complete product matrix covering both basic mass consumption and various segmented scenarios. Its product lines include not only classic series, premium soy sauce series, and time-honored series for daily cooking, but also healthy and nutritious lines such as organic, less-sodium, iron-fortified, selenium-enriched, and gluten-free products, as well as trendy products such as matsutake premium soy sauce.In the oyster sauce category, the company insists on selecting premium whole oysters from high-standard marine ranches and simmering them into sauce. With genuine ingredients and rigorous craftsmanship, Haitian oyster sauce maintains its advantage of being “rich in flavor, free from any fishy taste; one simple step to seal in freshness” . Currently, the company has launched diversified products such as Haitian superior oyster sauce and golden label oyster sauce, covering different flavors, packaging specifications, and price points. In response to consumer demand, the company has carried out scenario-based innovation, successively launching new products such as spicy oyster sauce and matsutake fresh oyster sauce to continuously enrich consumer choices.In the seasoning sauce category, the company’s products are mainly divided into two categories: basic flavored sauces and compound flavored sauces. It has built a product system with rich categories, diverse flavors, and multiple scenarios, such as Chu Hou Paste, Hoisin Sauce, Sauce for Rice, and Mushroom Sauce, which are suitable for different cooking methods. Meanwhile, the company adheres to a dual-wheel layout of “traditional vinegar + specialty vinegar,” developing regional characteristic rice vinegar such as sweet rice vinegar, selected fresh rice vinegar, and kangle vinegar, as well as specialty fruit vinegar including sugar-free apple cider vinegar and raw orange vinegar. This has formed a rich and diverse vinegar product system, further consolidating the company’s all-category competitive advantages, providing solid support for its steady performance growth, and building a profound market barrier.Benefiting from the recovery of the consumer market and its extensive product portfolio, Haitian Flavouring’s core categories including soy sauce, oyster sauce, and seasoning sauces maintained steady development in 2025, achieving operating revenues of RMB 14.934 billion, RMB 4.868 billion, and RMB 2.917 billion respectively, with year-on-year growth rates of 8.55%, 5.48%, and 9.29%. The three major categories maintained positive growth simultaneously, providing solid support for the overall performance.As of the end of 2025, Haitian Flavouring has established 7 product series each generating over RMB 1 billion in revenue, and more than 30 product series each exceeding RMB 100 million, with product concentration and competitiveness continuing to improve. Among them, the two products series of Golden Label Light Soy Sauce and Mushroom Dark Soy Sauce have been bestsellers for over 60 years. The two products series of Premium Soy Sauce and Haitian Superior Oyster Sauce have achieved annual revenue of over RMB 1 billion per product for over 10 consecutive years, becoming the core drivers supporting the Company's steady performance growth and demonstrating strong product vitality and high market recognition.While consolidating its advantages in core product categories, Haitian Flavouring proactively adapts to the trend of consumption upgrading, invests heavily in new product development, creates trend-setting new products, and forms a continuously evolving growth flywheel. Supported by its industry-leading product strength, the nutritionally healthy product series, represented by organic and less-sodium options, achieved operating revenue with a year-on-year growth rate of 48.3%, significantly outperforming the industry average growth rate and opening up a new growth curve for the Company's performance growth.Furthermore, Haitian Flavouring is proactively transforming itself from a "condiments supplier" to a "comprehensive flavor solutions provider," accurately capturing the new market opportunities brought by the industrialization and chain-upgrading of the catering industry. As of the end of 2025, the Company has cumulatively provided one-stop commercial condiment solutions to catering chains, food enterprises, and numerous global retail brands, further expanding its profit margins.Meanwhile, the Company boasts leading digitalization-enabled flexible production and customized service capabilities. It can produce up to over 20 specifications and more than 130 SKUs of different products on the same production line, with its customized service response and time-to-market speed leading the industry. Powered by its digital transformation, the Company's ultimate supply chain has established a new paradigm for the collaborative development of "customization, scale, quality-to-price performance ratio" in the manufacturing industry. This not only ensures stable and safe product quality to meet the stringent requirements of chain catering but also caters to the diverse needs of different users for condiments.Digitalization Empowers Across the Entire Chain, Technological Innovation Boosts EfficiencyTechnology development and technological innovation are the core engines driving Haitian Flavouring's performance growth. The Company proactively embraces the AI era, deeply integrating artificial intelligence and big data into the entire chain of R&D, production, supply, and sales. This promotes the organic integration of cutting-edge digital technologies with millennia-old brewing techniques, achieving a comprehensive leap in production efficiency, product quality, and operational effectiveness.Every year, Haitian maintained R&D investment at approximately 3% of its operating revenue, solidifying the foundation for innovation with a long-term perspective. Meanwhile, the Company’s Gaoming production base was successfully recognized as the world's first "Lighthouse Factory" in the soy sauce brewing industry, a benchmark for smart manufacturing certified by the World Economic Forum, redefining the Digitalization height of the traditional condiments industry.With comprehensive digital empowerment, Haitian's supply chain operational efficiency has significantly improved. In 2025, the Company's On-Time In-Full (OTIF) delivery rate continued to optimize, and customer service levels reached a new height. At the same time, the ratios of manufacturing expenses and direct labor costs to operating costs-two core cost indicators- surpassed those of most peers, achieving a dual breakthrough in quality improvement, efficiency enhancement, and cost control.Thanks to its outstanding digital practices, in 2025, the Company won numerous awards, including the "CGF China Supply Chain Digitalization and Sustainable Resilience Development Case" and the "National Typical Cases of Digital Transformation in Manufacturing", establishing itself as a benchmark for digital transformation in the industry. Additionally, the national standard " General Technical Requirements for Food Production Digital Factories", led by Haitian, was officially released. This fills the gap in the field of digital factory construction in China's food industry and provides authoritative and unified technical guidelines and an implementation framework for the Digitalization upgrading of the food industry.Leveraging smart technologies, the Company also achieved notable progress in green manufacturing. In terms of energy structure, the scale of solar photovoltaic power stations increased by nearly 100%, and a biomass power generation project was also put into operation. Power generated from green energy reached 29 million kWh, while the share of green electricity exceeded 28%. Through a smart water-saving system, the Company made dedicated efforts to set a benchmark in water conservation, recycling 1.88 million cubic meters of water over the past year, equivalent to the capacity of 752 standard swimming pools. In 2025, the Company implemented 128 energy-saving and carbon-reduction initiatives, these efforts resulted in a total reduction of 29,000 tonnes of carbon dioxide equivalent, marking a solid step forward in its green and low-carbon development.Accelerating Global Expansion, Charting a New Course on the World StageWhile maintaining its leading position and deepening its presence in the domestic market, Haitian Flavouring has been proactively expanding its international footprint and accelerating its pace to "set sail" for global markets. Adhering to a dual-track development approach of "global standards + local adaptation," the Company’s products are now sold in over 80 countries and regions worldwide. It has been named a "Chinese Brand Loved by Foreigners" for two consecutive years, reflecting its growing international influence and marking a transition from "product export" to "enterprise globalization."Recently, the Company successfully upgraded its British Retail Consortium (BRC) rating from Grade B to Grade A, a testament to its quality control system receiving internationally recognized accreditation and achieving a world-class standard. This accomplishment has instilled strong confidence in the Company’s efforts to further expand its global footprint and enter premium retail channels in Europe and the United States, while also underscoring the high quality and international competitiveness of Haitian’s products.On March 17, the Company was recognized as a Leading Enterprise in the 2026 Forbes China Pioneer Innovators in Industry Development Selection in recognition of its digital and intelligent transformation as well as its green development practices, affirming the Company’s long-term value creation.In June 2025, the Company was successfully listed on the Hong Kong Stock Exchange, marking a new milestone as it now operates on the dual A+H share platform. The listing attracted eight prominent domestic and international institutions, including Hillhouse Capital and the Government of Singapore Investment Corp (GIC), to serve as cornerstone investors, underscoring the international market's recognition of the Company's growth potential and providing ample capital to support its global expansion strategy. In the same year, the Company also established its overseas production base, further enhancing its global production and sales network. This provides a solid foundation for building a global supply chain and leveraging the Company's competitive advantages from the domestic market, marking a critical step forward in the execution of its internationalization strategy.On the brand development front, the Company continues to deepen its commitment to “400-Year Legacy of Oriental Flavor” Through iconic IPs such as Chef of China, it has captured widespread attention across Mainland China, Hong Kong, Macao, Taiwan, and beyond, creating a deep resonance between traditional brewing culture and modern consumer experiences. In addition, the Company launched the “Ambassador for Chinese Flavor” Initiative, bringing together collaborators to ignite global enthusiasm for authentic Chinese cuisine.Overall, in 2025, Haitian Flavouring delivered an impressive performance, driven by its steady operations and forward-looking strategy. Building on a comprehensive product matrix and leveraging digital empowerment, the Company has successfully achieved a strategic transformation through in-depth, full-channel operations. This has enabled it to establish a core competitive edge capable of withstanding market volatility and navigating industry cycles.Looking ahead, the Company will continue to uphold its dedication to craftsmanship and innovation, further consolidate its leading position in the domestic market, and steadily accelerate its global expansion. By doing so, it aims to support the high-quality development of the traditional condiment industry, bring the taste of China to the world, and continue to lead the industry toward a new era of higher quality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com